Skip to content

Above 180/120? See warning signs

SevereHypertension

Iloprost Inhalation Solution (Ventavis) for Severe Pulmonary Arterial Hypertension

Severe Hypertension NetworkPublished May 19, 20101 min read

Key points

  • 29, the FDA approved iloprost inhalation solution (Ventavis, made by CoTherix, Inc.), for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association (NYHA) Class III or IV symptoms.
  • The approval was based on the results of a controlled trial comparing the effects of repeated daily inhalations of iloprost (2.5- or 5.0-micrograms 6 to 9 times daily) with placebo in 203 adult patients with selected forms of severe PAH and chronic thromboembolic pulmonary hypertension, NYHA functional class III or IV.
  • The most commonly reported adverse events included flushing, increased cough, hypotension, headaches, nausea, trismus, and syncope.
  • The synthetic prostacyclin analog is intended for administration with Prodose Adaptive Aerosol Delivery (AAD) system.

On Dec. 29, the FDA approved iloprost inhalation solution (Ventavis, made by CoTherix, Inc.), for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association (NYHA) Class III or IV symptoms.

The synthetic prostacyclin analog is intended for administration with Prodose Adaptive Aerosol Delivery (AAD) system. According to a company news release, the non-invasive nature of the system is expected to increase patient compliance and avoid complications associated with intravenous or subcutaneous prostacyclin delivery.

The approval was based on the results of a controlled trial comparing the effects of repeated daily inhalations of iloprost (2.5- or 5.0-micrograms 6 to 9 times daily) with placebo in 203 adult patients with selected forms of severe PAH and chronic thromboembolic pulmonary hypertension, NYHA functional class III or IV. The median inhaled dose of iloprost was 30 micrograms/day.

At three months, 16.8% of patients receiving iloprost showed significant improvement in symptoms (at least one NYHA class), and exercise tolerance (minimum 10% increase in six-minute walking distance), compared with 4.9% of patients receiving placebo ( P = .0033).

Iloprost was generally well tolerated. The most commonly reported adverse events included flushing, increased cough, hypotension, headaches, nausea, trismus, and syncope.

Iloprost inhalation solution was previously approved for this indication in several European countries and Australia, where it is marketed by Schering AG.

– –
by Yael Waknine
FDA Approvals: Ventavis, Kepivance, Captique

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A reading above 180/120 with chest pain, shortness of breath, weakness or vision changes is an emergency: call 911 or your local emergency number.

Hypertensive crisis

Above 180/120? Know when it’s an emergency.

Wait five minutes and measure again. If your reading is still this high and you have any of these symptoms, call 911 or your local emergency number. Don’t wait to see if it comes down on its own.

  • Chest pain
  • Shortness of breath
  • Back pain
  • Numbness or weakness
  • Change in vision
  • Difficulty speaking

No symptoms but still above 180/120 after a second reading? Contact your doctor straight away. Outside the US, call your local emergency number.